Sartorius Stedim Biotech (XPAR:DIM) Cyclically Adjusted PS Ratio: (As of Jul. 25, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XPAR:DIM Sartorius Stedim Biotech SA XPAR:DIM
90 GF Score
Price €167.30
GF Value €201.85
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Sartorius Stedim Biotech Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Sartorius Stedim Biotech  (XPAR:DIM) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Sartorius Stedim Biotech Cyclically Adjusted PS Ratio Related Terms


Sartorius Stedim Biotech Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Sartorius Stedim Biotech's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sartorius Stedim Biotech Cyclically Adjusted PS Ratio Chart

Sartorius Stedim Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 14.68 10.46 7.53 7.80

Sartorius Stedim Biotech Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.78 6.54 7.80 6.06 0.00

XPAR:DIM vs ISRG, BDX, MDLN: Cyclically Adjusted PS Ratio Comparison

For the Medical Instruments & Supplies subindustry, Sartorius Stedim Biotech's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sartorius Stedim Biotech Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sartorius Stedim Biotech's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Sartorius Stedim Biotech's Cyclically Adjusted PS Ratio falls into.


XPAR:DIM
90GF Score
Sartorius Stedim Biotech SA XPAR:DIM
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sartorius Stedim Biotech Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Sartorius Stedim Biotech's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Sartorius Stedim Biotech's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=7.904/131.3638*131.3638
=7.904

Current CPI (Jun. 2026) = 131.3638.

Sartorius Stedim Biotech Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201512 0.000 99.717 0.000
201606 2.878 100.717 3.754
201612 0.000 101.217 0.000
201706 2.977 102.117 3.830
201709 2.776 102.717 3.550
201712 3.002 102.617 3.843
201803 3.024 102.917 3.860
201806 3.283 104.017 4.146
201809 3.393 104.718 4.256
201812 3.450 104.217 4.349
201903 3.729 104.217 4.700
201906 3.958 105.718 4.918
201909 3.957 106.018 4.903
201912 3.931 105.818 4.880
202003 4.577 105.718 5.687
202006 4.847 106.618 5.972
202009 5.523 105.818 6.856
202012 5.780 105.518 7.196
202103 7.083 107.518 8.654
202106 7.553 108.486 9.146
202109 8.191 109.435 9.832
202112 8.443 110.384 10.048
202203 9.353 113.968 10.781
202206 9.348 115.760 10.608
202209 9.546 118.818 10.554
202212 9.653 119.345 10.625
202303 7.908 122.402 8.487
202306 7.310 123.140 7.798
202309 7.173 124.195 7.587
202312 7.692 123.773 8.164
202403 6.858 125.038 7.205
202406 7.420 125.882 7.743
202409 6.683 126.198 6.957
202412 7.731 127.041 7.994
202503 7.655 127.779 7.870
202506 7.613 128.412 7.788
202509 7.255 129.255 7.373
202512 7.976 129.361 8.100
202603 7.866 131.258 7.872
202606 7.904 131.364 7.904

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Sartorius Stedim Biotech (XPAR:DIM) Overvalued in 2026?

Based on GuruFocus' analysis, Sartorius Stedim Biotech stock appears to be undervalued. The current stock price of €167.30 is trading 17.1% below its estimated GF Value™ of €201.85. GuruFocus considers Sartorius Stedim Biotech to be Modestly Undervalued.

Key valuation signals for XPAR:DIM:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: €201.85 vs. price of €167.30 (17.1% below fair value)
  • GF Score™: 90/100 with 5 warning signs

No single metric tells the full story. See the XPAR:DIM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sartorius Stedim Biotech Business Description

Address Otto-Brenner-Strasse 20, Goettingen, DEU, 37079
Sartorius Stedim Biotech is a leading provider of bioprocessing solutions. It sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs and has a focus on single-use technology. It is a subsidiary of Sartorius AG, which has 71.5% ownership and 83% voting control. The business is geographically diverse, with 35% of sales from the Americas, 42% from Europe, the Middle East, and Africa, 15% from Asia excluding China, and 8% from China.
90GF Score

Get the complete analysis for XPAR:DIM

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€167.30
Price
€201.85
GF Value